Current Edition

AbbVie and J&J dominate clinical trial development in psoriatic arthritis, says GlobalData

AbbVie and Johnson & Johnson (J&J) are responsible for 47 of the 121 industry sponsored clinical trials in the psoriatic arthritis space, according to GlobalData, a leading data and analytics company.
The company’s latest report: ‘Psoriatic Arthritis: Competitive Landscape to 2026’ found that industry sponsors are responsible for over 70% of psoriatic arthritis clinical trials, with the top seven industry sponsors accounting for 64% of all industry sponsored trials.
Alexandra Annis, MS, Managing Pharma Analyst at GlobalData, says: “AbbVie and J&J have held a strong presence in the psoriatic arthritis space since the launch of their anti-tumor necrosis factor therapies Humira in 2006 and Remicade in 2004, respectively. AbbVie and J&J have launched or are developing biologics with novel mechanisms of action, including interleukin inhibitors, maintaining their position in the psoriatic arthritis space.”

J&J and AbbVie have been the dominant players in the psoriatic arthritis market since the introduction of Remicade (2004) and Humira (2005) as the second and third TNF inhibitors approved by the FDA, respectively.
Annis concludes: “The PsA market has become increasingly competitive, with both subcutaneous and intravenous therapies being available as well as two oral small molecule and biosimilars. However, J&J and AbbVie are slated to remain headliners in the psoriatic arthritis marketplace, looking to capitalize on the excitement surrounding interleukin inhibitors and janus kinase inhibitors.”